Data Readout

NeOnc's NEO100 heads toward an interim readout in a glioma trial with no direct rival

NeOnc Technologies expects an interim look at its fully enrolled Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma sometime in the second half of 2026, seven years after the trial's original completion target.

By AppliedXLJuly 14, 2026Trial NCT02704858

Executive Summary

NeOnc Technologies is heading toward an interim analysis of its fully enrolled glioma trial, the only industry-sponsored study testing this mechanism in this exact patient population.
The trial's completion date has been pushed back repeatedly over nearly a decade, a pattern that bears directly on whether the newly stated second-half-2026 window holds.
No peer trial shares both the target and the indication, so the readout will not be benchmarked against a rival program; it will instead be the first clinical data point for this mechanism in this disease.
A clinically meaningful interim signal would establish proof of concept for a mechanism that has otherwise gone untested in recurrent IDH1-mutant high-grade glioma, while a delay or a weak signal would extend a multi-year pattern of slipped guidance without a compensating data point.

The catalyst

NeOnc Technologies Holdings, Inc. said its Phase 2a study of NEO100 (perillyl alcohol) in recurrent IDH1-mutant high-grade glioma remains fully enrolled, with an interim analysis expected later in 2026. The trial, registered as NCT02704858, is testing NEO100 in patients with Grade III or IV IDH1-mutated glioma who have progressed after prior treatment. NeOnc's chief executive, Amir Heshmatpour, described the company as entering "a defining phase" with "near-term data readouts and regulatory alignment" for its central nervous system programs. NeOnc+1

The completion-date pattern

The trial's primary completion date has moved six times since 2020: from June 2020 to June 2021, to June 2022, to June 2024, to December 2024, to October 2025, and most recently to March 30, 2026. Enrollment target rose from 43 to 49 patients over the same stretch, a change registered alongside the first completion-date revision in August 2020. The trial has carried a Recruiting status continuously since it started in August 2017, and no results have posted on ClinicalTrials.gov to date. NCT02704858

Guidance since May

NeOnc's public guidance on the readout window has itself moved within a matter of weeks. A May 5, 2026 disclosure pointed to an interim analysis "later this year", and subsequent guidance narrowed to a July 2026 window before widening back out to the July-through-December 2026 half-year range currently in effect. That narrowing-then-widening pattern, layered on top of the multi-year history of completion-date revisions, is the operational context against which the stated window should be read. NeOnc

The competitive frame

No other industry trial tests a farnesyltransferase inhibitor against this exact target-indication pairing, recurrent IDH1-mutant high-grade glioma; the nearest comparators in the space share only the disease setting or the small-molecule modality, including IDH1-targeted agents such as Nuvation Bio's safusidenib (NCT05303519) and Servier's vorasidenib (NCT07286292), which work through a different mechanism. Field activity around the farnesyltransferase target has declined, with 22 recent trials against 462 older ones across all indications. That combination, a mechanism with no peer testing it in this disease and a target class with declining overall trial activity, means the interim analysis will be read as an isolated data point rather than one benchmarked against a rival program.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.